Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vertex Pharmaceuticals (NQ:VRTX)

393.21 -1.32 (-0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Here's why you can't find a Wall Street analyst who will tell you to sell this stock. 
Via The Motley Fool
Topics Intellectual Property
3 Absurdly Cheap Stocks to Buy for the Long Haul
They trade at some incredibly low earnings multiples. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
 
Via Benzinga
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Technical Breakout Potential
Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors. 
Via Chartmill
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones. 
Via The Motley Fool
1 Safe-and-Steady Stock to Research Further and 2 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Why This Biotech Company Could Be a Growth Stock Powerhouse
Recent developments aren't as devastating to the company's prospects as some might think. 
Via The Motley Fool
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
 
Via Benzinga
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Top GARP Stock with Strong Growth and Reasonable Valuation
Vertex Pharmaceuticals (VRTX) exemplifies the GARP strategy with strong growth, a reasonable valuation, high profitability, and a robust debt-free balance sheet. 
Via Chartmill
Tuesday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
 
Via Benzinga
3 No-Brainer Stocks to Buy Right Now
Investing in these pharmaceutical stocks is an easy decision. 
Via The Motley Fool
Topics World Trade
My 2 Favorite Stocks to Buy Right Now
Looking for good investing ideas? These two stocks could be huge winners for long-term investors. 
Via The Motley Fool
Topics Artificial Intelligence
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
What's Driving the Market Sentiment Around Vertex Pharmaceuticals?
 
Via Benzinga
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Prime Candidate for Value Investors
Vertex Pharmaceuticals (VRTX) is a top value stock with strong financials, high profitability, and impressive growth, trading below its biotech peers. 
Via Chartmill
This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy?
It's been an unusually bad year for this drugmaker, but it's essential to look beyond that. 
Via The Motley Fool
Topics Law Enforcement Stocks
2 Beaten-Down Stocks With Incredible Upside Potential
These stocks should be able to rebound strongly. 
Via The Motley Fool
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
What's Wrong With Vertex Pharmaceuticals Stock?
Shares of the pharma company are down 17% in the past 12 months. 
Via The Motley Fool
2 Nasdaq 100 Stocks to Consider Right Now and 1 Facing Challenges
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
Trump 2.0 At 200 Days: Palantir Surges, Tesla Slumps
Palantir leads all stocks in the S&P 500 with a stunning 160% gain in Trump's first 200 days. 
Via Benzinga
Topics Government Stocks
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
This biotech's innovative approach could pay rich dividends down the road. 
Via The Motley Fool
3 Fantastic Growth Stocks to Buy in August
Only one of these growth stocks is up big so far in 2025. But all three could be huge winners over the next few years. 
Via The Motley Fool
Is This Beaten-Down Stock a Buy on the Dip?
It's the second time this year the stock has slumped significantly in one day, and it might represent another attractive entry point. 
Via The Motley Fool
2 Growth Stocks That Are No-Brainer Buys Right Now
These stocks have outperformed broader equities over the past decade and still have room to run. 
Via The Motley Fool
VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the... 
Via StockStory
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
 
Via Benzinga
Vertex Pharmaceuticals's Options Frenzy: What You Need to Know
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.